Functional imaging of colorectal cancer: positron emission tomography, magnetic resonance imaging, and computed tomography.

abstract：:The use of adjuvant chemotherapy has improved survival in early-stage colon cancer. Ongoing adjuvant clinical trials are evaluating the addition of targeted therapies to standard chemotherapy regimen. Preliminary results with bevacizumab were disappointing. Also, cetuximab added to chemotherapy does not seem to be bet...

journal_title：Clinical colorectal cancer

authors： Chibaudel B,Tournigand C,André T,Larsen AK,de Gramont A

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:The primary objective of this study was to determine the long-term outcome of sphincter preservation with preoperative radiation therapy (RT) and surgical resection in the treatment of distal rectal adenocarcinoma. PATIENTS AND METHODS:Between April 1988 and December 1996, 36 (cT2, n=9; cT3, n=27) patients ...

journal_title：Clinical colorectal cancer

authors： Rengan R,Paty PB,Wong WD,Guillem JG,Weiser M,Temple L,Saltz L,Minsky BD

更新日期：2006-03-01 00:00:00

abstract：PURPOSE:The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations. Capecitabine is also at least as effective as bolus 5-FU/LV i...

journal_title：Clinical colorectal cancer

authors： Twelves CJ,Butts CA,Cassidy J,Conroy T,Braud Fd,Diaz-Rubio E,Tabernero JM,Schoffski P,Figer A,Brunet R,Grossmann J,Sobrero AF,Van Cutsem EJ

更新日期：2005-07-01 00:00:00

abstract：BACKGROUND:Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. MATERIALS AND METHODS:The Harris Health System (HHS) is an integrated health delivery network that provides medical car...

journal_title：Clinical colorectal cancer

authors： Lau-Min K,Prakash P,Jo E,Thrift AP,Hilsenbeck S,Musher BL

更新日期：2020-06-01 00:00:00

abstract：INTRODUCTION:The aim of this study was to evaluate the efficacy and safety of maintenance therapy with axitinib versus placebo following induction therapy in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In this double-blinded, phase II trial, patients with mCRC who had not progressed after 6...

journal_title：Clinical colorectal cancer

authors： Grávalos C,Carrato A,Tobeña M,Rodriguez-Garrote M,Soler G,Vieitez JM,Robles L,Valladares-Ayerbes M,Polo E,Limón ML,Safont MJ,Martínez de Castro E,García-Alfonso P,Aranda E,Spanish Cooperative Group for the Treatment of Digest

更新日期：2018-06-01 00:00:00

abstract：BACKGROUND:Anterior resection syndrome (ARS) is common after sphincter-saving surgery for rectal cancer. It includes changes in the frequency and urgency of bowel movements and fecal incontinence. The therapeutic efficacy of biofeedback on ARS is unclear. We sought to evaluate the effectiveness of biofeedback therapy i...

journal_title：Clinical colorectal cancer

authors： Liang Z,Ding W,Chen W,Wang Z,Du P,Cui L

更新日期：2016-09-01 00:00:00

abstract：INTRODUCTION:Patients with metastatic colorectal cancer (CRC) may present with oligometastatic lung lesions for which stereotactic ablative radiotherapy (SABR) can be utilized. This study aims to report efficacy and prognostic factors associated with colorectal lung metastases treated with SABR. MATERIAL AND METHODS:T...

journal_title：Clinical colorectal cancer

authors： Kinj R,Bondiau PY,François E,Gérard JP,Naghavi AO,Leysalle A,Chamorey E,Evesque L,Padovani B,Ianessi A,Benezery K,Doyen J

更新日期：2017-09-01 00:00:00

abstract：:Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal cancer of teh gastrointestinal tract. They are characterized by the expression of KIT. Therapeutically, metastatic GISTs are effectively treated by imatinib, a tyrosine kinase inhibitor (TKI) with activity against KIT and platelet-derived growth f...

journal_title：Clinical colorectal cancer

authors： von Mehren M

更新日期：2006-11-01 00:00:00

abstract：:The multiplicity of chemotherapy regimens currently available to treat colorectal cancer in the first-line setting precludes the identification of a single standard regimen for front-line therapy. The previous standard, 5-fluorouracil (5-FU), formerly the only agent with any significant activity against colorectal can...

journal_title：Clinical colorectal cancer

authors： Goldberg RM

更新日期：2004-06-01 00:00:00

abstract：:Local excision is an alternative approach to radical proctectomy for rectal cancer, but from an oncologic standpoint, it is a compromise, and its role remains controversial. Careful patient selection is essential because local excision is generally considered only for early rectal cancer with no evidence of nodal meta...

journal_title：Clinical colorectal cancer

authors： Kim E,Hwang JM,Garcia-Aguilar J

更新日期：2008-11-01 00:00:00

abstract：BACKGROUND:We performed a meta-analysis of previous reports evaluating the effect of mFIO (modified FOLFIRINOX; leucovorin, 5-fluorouracil, irinotecan, oxaliplatin) regimens in advanced pancreatic cancer. MATERIALS AND METHODS:We performed a meta-analysis of reported studies in PubMed, Scopus, and Web of Science (1950...

journal_title：Clinical colorectal cancer

authors： Usón Junior PLS,Rother ET,Maluf FC,Bugano DDG

更新日期：2018-09-01 00:00:00

abstract：INTRODUCTION:Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU. Given the additional benefit of oxaliplatin over FP alone in the management of color...

journal_title：Clinical colorectal cancer

authors： Chakrabarti S,Sara J,Lobo R,Eiring R,Finnes H,Mitchell J,Hartgers M,Okano A,Halfdanarson T,Grothey A

更新日期：2019-03-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR) has been validated as an important target in the treatment of metastatic colorectal cancer (mCRC). While initial studies focused on the treatment of disease that was refractory to available chemotherapy agents, 2 recent themes have emerged: the use of KRAS mutation status to sel...

journal_title：Clinical colorectal cancer

authors： Stein S,Cohen DJ,Hochster HS

更新日期：2010-06-01 00:00:00

abstract：INTRODUCTION:In studies of colorectal cancer, the elderly have been frequently underrepresented because comorbid conditions and functional status often lead to study exclusion. For elderly patients with an indication for neoadjuvant chemoradiotherapy (nCRT), physicians usually decide using clinical factors whether nCRT...

journal_title：Clinical colorectal cancer

authors： Jacobs L,van der Vlies E,Ten Bokkel Huinink D,Bloemendal H,Intven M,Smits AB,Weusten BLAM,Siersema PD,van Lelyveld N,Los M

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:The novel severe acute respiratory syndrome coronavirus 2 virus that emerged in December 2019 causing coronavirus disease 2019 (COVID-19) has led to the sudden national reorganization of health care systems and changes in the delivery of health care globally. The purpose of our study was to use a survey to a...

journal_title：Clinical colorectal cancer

authors： Nunoo-Mensah JW,Rizk M,Caushaj PF,Giordano P,Fortunato R,Dulskas A,Bugra D,da Costa Pereira JM,Escalante R,Koda K,Samalavicius NE,Maeda K,Chun HK,ISUCRS COVID-19 Participating Investigator Group.

更新日期：2020-09-01 00:00:00

abstract：:Significant advances have been made with respect to our understanding of the critical role of agents targeting angiogenic pathways in the treatment of metastatic colorectal cancer (mCRC). The approval of 3 agents that target angiogenic signaling, bevacizumab, ziv-aflibercept, and regorafenib, provides strong evidence ...

journal_title：Clinical colorectal cancer

authors： Lee JJ,Chu E

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:Screening protocols for colorectal cancer are broadly recommended and effective in reducing mortality. However, populations from different age groups can harbor distinct pathologic and molecular profiles that can also be influenced by screening and polyp resection, especially in older ages. PATIENTS AND MET...

journal_title：Clinical colorectal cancer

authors： Pereira AAL,Fernandes GDS,Braga GTP,Marchetti KR,Mascarenhas CDC,Gumz B,Crosara M,Dib L,Girardi D,Barrichello A,Seidler H

更新日期：2020-12-01 00:00:00

abstract：:The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has ushered in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). The anti-EGFR monoclonal antibodies cetuximab and panitu...

journal_title：Clinical colorectal cancer

authors： Lee MS,Kopetz S

更新日期：2015-12-01 00:00:00

abstract：:Adjuvant therapy can reduce the risk of disease recurrence in patients with stage II-IV colorectal cancer. Recently, 3 monoclonal antibodies have been shown to improve clinical outcome in this group of patients. Bevacizumab is an antiangiogenesis agent that has been shown in clinical and preclinical models to reverse ...

journal_title：Clinical colorectal cancer

authors： Wadler S

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:The optimal therapeutic strategy for metastatic colorectal cancer patients is still a matter of debate. There are no prognostic variables indicating how many lines individual patients ought to receive, and whether later lines could be effective even when earlier ones were not. PATIENTS AND METHODS:We retros...

journal_title：Clinical colorectal cancer

authors： Tampellini M,Di Maio M,Baratelli C,Anania L,Brizzi MP,Sonetto C,La Salvia A,Scagliotti GV

更新日期：2017-12-01 00:00:00

abstract：INTRODUCTION:The aim of this study was to evaluate the efficacy and toxicity of molecular targeted agents plus chemotherapy compared with chemotherapy alone as second-line therapy for patients with metastatic colorectal cancer (mCRC). MATERIALS AND METHODS:We identified randomized controlled trials that compared molec...

journal_title：Clinical colorectal cancer

authors： Pei X,Liu Y,Sun L,Zhang J,Fang Y,Liao X,Liu J,Zhang C,Yin T

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:Similar epidemiologic characteristics suggest a common etiology for colon cancer (CC) and diverticular disease of the colon (DD). The relationship between the 2 diseases is still unclear, and the impact of DD in patients diagnosed with CC on disease-free survival (DFS) and overall survival (OS) is unknown. N...

journal_title：Clinical colorectal cancer

authors： Soran A,Harlak A,Wilson JW,Nesbitt L,Lembersky BC,Wienad HS,O'Connell MJ

更新日期：2006-07-01 00:00:00

abstract：:To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current trea...

journal_title：Clinical colorectal cancer

authors： Goldstein DA,Zeichner SB,Bartnik CM,Neustadter E,Flowers CR

更新日期：2016-03-01 00:00:00

abstract：:Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical activities inadequate if based only on the reduction of the tumor dimensions, as this may not reflect thei...

journal_title：Clinical colorectal cancer

authors： Manzoni M,Comolli G,Torchio M,Mazzini G,Danova M

更新日期：2015-03-01 00:00:00

abstract：:Combination protocols of 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan or oxaliplatin have demonstrated high activity in metastatic colorectal cancer. Capecitabine, an oral 5-FU prodrug, may replace infusional 5-FU/LV in combination protocols with irinotecan or oxaliplatin. We therefore initiated a phase II stud...

journal_title：Clinical colorectal cancer

authors： Jordan K,Kellner O,Kegel T,Schmoll HJ,Grothey A

更新日期：2004-05-01 00:00:00

abstract：BACKGROUND:Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and effectiveness of targeted therapies in first-line mCRC treatment according to age. PATIENTS AND...

journal_title：Clinical colorectal cancer

authors： Gouverneur A,Coutureau J,Jové J,Rouyer M,Grelaud A,Duc S,Gérard S,Smith D,Ravaud A,Droz C,Bernard MA,Lassalle R,Forrier-Réglat A,Noize P,ETNA study group and the EREBUS study group.

更新日期：2019-03-01 00:00:00

abstract：:Adult intussusception is a rare occurrence and, unlike in childhood, is usually associated with an underlying tumor. Although computed tomography (CT) imaging can identify an intussusception and point toward a cause, diagnosis is challenging if it is only intermittent. When an intussusception presents in the context o...

journal_title：Clinical colorectal cancer

authors： Chand M,Bradford L,Nash GF

更新日期：2008-05-01 00:00:00

abstract：BACKGROUND:Systemic chemotherapy increases the possibility of resection in patients with initially unresectable colorectal cancer (CRC), especially patients with hepatic metastasis. However, the predictive factors and prognosis of conversion to resection after chemotherapy in patients with various organ metastases rema...

journal_title：Clinical colorectal cancer

authors： Nozawa H,Ishihara S,Kawai K,Hata K,Kiyomatsu T,Tanaka T,Nishikawa T,Otani K,Yasuda K,Sasaki K,Kaneko M,Murono K

更新日期：2018-03-01 00:00:00

abstract：BACKGROUND:The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 20) metastatic colorectal cancer. PATIENTS AND METHODS:Patients w...

journal_title：Clinical colorectal cancer

authors： Shapiro JD,Thavaneswaran S,Underhill CR,Robledo KP,Karapetis CS,Day FL,Nott LM,Jefford M,Chantrill LA,Pavlakis N,Tebbutt NC,Price TJ,Khasraw M,Van Hazel GA,Waring PM,Tejpar S,Simes J,Gebski VJ,Desai J,Segelov E

更新日期：2018-12-01 00:00:00

abstract：BACKGROUND:Few patients with metastatic colorectal cancer (mCRC) are candidates for resection of their hepatic disease. Yttrium-90 ((90)Y) radioembolization has promise in the treatment of unresectable mCRC. We conducted a retrospective study to assess the efficacy in patients with refractory mCRC who underwent (90)Y r...

journal_title：Clinical colorectal cancer

authors： Martin LK,Cucci A,Wei L,Rose J,Blazer M,Schmidt C,Khabiri H,Bloomston M,Bekaii-Saab T

更新日期：2012-09-01 00:00:00